Extended-spectrum beta-lactamases in clinical isolates of Escherichia coli and Klebsiella spp. in a Singapore hospital: Clinical spectrum

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 3, 2004, Pages 302-306

  Chlebicki, Maciej Piotr ^a   Oh, H M L ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Beta lactam resistance; Beta lactamases; Escherichia coli infections; Klebsiella infections

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM;

ACUTE KIDNEY FAILURE; ANTIBIOTIC SENSITIVITY; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; BLOOD CULTURE; CONTROLLED STUDY; DECUBITUS; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FEMALE; GENERAL HOSPITAL; HEPATOBILIARY DISEASE; HUMAN; KLEBSIELLA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; SEPTIC SHOCK; SINGAPORE; SPUTUM CULTURE; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE CULTURE;

EID: 3142721345     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001;119:S397-404.
2. Rice L. Evolution and clinical importance of extended-spectrum beta-lactamases. Chest 2001;119:S391-6.
3. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
4. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
5. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
6. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118-24.
7. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation of cephalosporins. Ann Intern Med 1993;119:353-8.
8. Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 2001;5:189-95.
9. Murthy R. Implementation of strategies to control antimicrobial resistance. Chest 2001;119:S405-11.
10. Goldmann DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant micro-organisms in hospitals: a challenge to hospital leadership. JAMA 1996;275:234-40.
11. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998;280:1233-7.
12. Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000;21:455-8.
13. Patterson JE. Antibiotic utilization: is there an effect on antimicrobial resistance? Chest 2001;119:S426-30.
14. Jarlier V, Nicolas MH, Fournier G, Philippon A, Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-78.
15. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Ninth Informational Supplement. Vol. 19 No. 1. Villanova, PA: NCCLS, 1999.
16. Bentley DW, Bradley S, High K, Schoenbaum S, Taler G, Yoshikawa TT. Practice guideline for evaluation of fever and infection in long-term care facilities. Clin Infect Dis 2000;31:640-53.
17. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. 1988. Am J Infect Control 1988;16:128-40.
18. Vergis EN, Brennen C, Wagener M, Muder R. Pneumonia in long-term care: a prospective case-control study of risk factors and impact on survival. Arch Intern Med 2001;161:2378-81.
19. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN. Prevalence of extended spectrum beta-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 2002;42:193-8.
20. Gantz NM, Brown RB, Berk SL, Esposito AL, Gleckman RA. Manual of clinical problems in infectious diseases. Philadelphia: Lippincott Williams & Wilkins. 1999.
21. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc 1999;74:519-28.
22. Thomson KS, Moland ES. Cefipime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-54.
23. Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997;103:51-9.
24. Fierer J, Guiney D. Extended-spectrum beta-lactamases: a plague of plasmids. JAMA 1999;281:563-4.
25. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000;6:460-3.